Katsuda Masahiro, Iwahashi Makoto, Matsuda Kenji, Miyazawa Motoki, Nakamori Mikihito, Nakamura Masaki, Naka Teiji, Ojima Toshiyasu, Iida Takeshi, Yamaue Hiroki
Second Dept. of Surgery, School of Medicine, Wakayama Medical University.
Gan To Kagaku Ryoho. 2011 Nov;38(12):1942-4.
Patients with advanced carcinoma are thought to have an impaired immune surveillance system. Therefore, the potent helper action is required for the induction of an antitumor immune response in such patients. We evaluated the efficacy of CpG-ODN, which is TLR-9 agonist, as cancer vaccine adjuvant through in vitro experiments. We also conducted a phase I clinical trial for patients with advanced esophageal squamous cell carcinoma (ESCC) using peptide vaccine in combination with CpG-B. In vitro experiments showed that CpG-ODN caused various immune-modifications, suggesting an efficacy of CpG-ODN as peptide vaccine adjuvant. Moreover, the immune monitoring data in phase I clinical trial suggested that CpG-B augmented the generation of antigen-specific T cell responses and innate immunity. These data indicated that the vaccination with cancer-testis antigen derived peptide in combination with CpG-B may be useful as a new immunotherapy for patients with advanced ESCC.
晚期癌症患者被认为存在免疫监视系统受损的情况。因此，在此类患者中诱导抗肿瘤免疫反应需要强大的辅助作用。我们通过体外实验评估了作为Toll样受体9（TLR-9）激动剂的CpG寡脱氧核苷酸（CpG-ODN）作为癌症疫苗佐剂的疗效。我们还对晚期食管鳞状细胞癌（ESCC）患者进行了一项I期临床试验，使用肽疫苗联合CpG-B。体外实验表明，CpG-ODN引起了各种免疫调节，提示CpG-ODN作为肽疫苗佐剂具有疗效。此外，I期临床试验中的免疫监测数据表明，CpG-B增强了抗原特异性T细胞反应的产生以及固有免疫。这些数据表明，用癌-睾丸抗原衍生肽联合CpG-B进行疫苗接种可能作为晚期ESCC患者的一种新的免疫疗法。
